Results 101 to 110 of about 7,115 (194)

Olmesartan-associated enteropathy: results of a national survey

, 2014
BACKGROUND: Recently, a new enteropathy has been described: olmesartan-associated enteropathy. However, the association has been questioned: a phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan.
Marthey, L., Cadiot, G, Gompel, M, Gompel, M., Lacroute, J., Cadiot, G., Peschard, S, Poncin, E., Salloum, H., Malamut, G, Seksik, P, Mesnard, B., Poncin, E, Zerbib, F, Druez, A., Parlier, D., Seksik, P., Eoche, M., Chayvialle, J A, Pouderoux, P., Peschard, S., Cerf-Bensussan, N, Parlier, D, Abitbol, V., Bobichon, R., Mesnard, B, Pouderoux, P, Bobichon, R, Malamut, G., Carbonnel, F., Zerbib, F., Wils, P, Savoye, G., Lacroute, J, Skinazi, F., Chayvialle, J. A., Eoche, M, Abitbol, V, Savoye, G, Wils, P., Méresse, B, Cerf-Bensussan, N., Méresse, B., Marthey, L, Colardelle, P., Salloum, H, Druez, Anne, Carbonnel, F, Colardelle, P, Skinazi, F   +49 more
core   +1 more source

Analysis Of Olmesartan Medoxomil, Hydrochlorothiazide, And Related Impurities In Pharmaceutical Dosage Forms By Hplc

, 2014
Çalışmamızda antihipertansif etkili ilaç etken maddeleri, Olmesartan medoksomil ve Hidroklorotiyazid ve bu etken maddelerin safsızlıklarının aynı anda tayinleri amacıyla bir Agilent 1100 serisi HPLC yöntemi geliştirilmiş ve valide edilmiştir.
SAÇINTI, Çağlar
core  

Olmesartan [PDF]

, 2020
openaire   +1 more source

Il ruolo della associazione precostituita Olmesartan/Amlodipina

, 2016
Profilo farmacologico e razionale di impiego della associazione precostituita Olmesartan/Amlodipina nella terapia della ipertensione arteriosa, nel paziente iperteso diabetico e nel paziente iperteso ...
Genovese, S., BORGHI, CLAUDIO
core   +1 more source

Supplementary Material for: Severe hepatitis complicating olmesartan enteropathy

Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose ...
Tabatabai S. (18306649), Kuan C.C. (18306643), Abasszade J.H. (18306637), Tan R. (9941279), Dhillon H. (18306640), Worland T. (18306646)   +5 more
core   +1 more source

A Thermoresponsive In Situ Salified Self-Nanoemulsifying Drug Delivery System of Olmesartan Medoxomil: Overcoming Leakage and Drug Trapping Limitations. [PDF]

Pharmaceutics
Sherif AY, Altamimi MA, Elzayat EM.
europepmc   +1 more source

Ramipril and Olmesartan: Unveiling their pleiotropic potential as immunomodulators. [PDF]

Indian J Pharmacol
Dasan J, Yesunesan A, Chandran V, Mathew J, Mathew L.   +4 more
europepmc   +1 more source

Disarming Pseudomonas aeruginosa: repurposing vardenafil, valsartan, and olmesartan as anti-virulence and antibiofilm agents. [PDF]

Sci Rep
Mahfouz AA, Abbas HA, Yousef N, Elgaml A.   +3 more
europepmc   +1 more source

Blood pressure lowering efficacy of sacubitril/allisartan versus olmesartan in elderly Chinese hypertensive patients. [PDF]

J Geriatr Cardiol
Zhang W, Yan J, Zhang J, Ge Q, Lu XH, Xu WJ, Sun JC, Mu SM, Chen Y, Liu ZC, Wang Q, Zhou XN, Li Y, Wang JG.   +13 more
europepmc   +1 more source

Comparative bleeding risk between angiotensin II receptor blockers with high versus low P-glycoprotein inhibitory activity in patients with atrial fibrillation receiving direct oral anticoagulants. [PDF]

Hypertens Res
Kim S, You SC, Il Kim S, Bae JH, Choi JI, Park S.   +5 more
europepmc   +1 more source